SciRhom
SciRhom GmbH is a clinical-stage German biotech developing first-in-class anti-iRhom2 monoclonal antibody therapies for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
- Company typePrivate
- Founded2016
- HeadquartersMartinsried, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SciRhom does
SciRhom GmbH is a privately held, clinical-stage biopharmaceutical company founded in 2016 in Martinsried, Germany, that develops first-in-class humanized monoclonal antibodies targeting iRhom2 (inactive Rhomboid 2 / RHBDF2), a key upstream regulator of the TACE/ADAM17 protease. By inhibiting iRhom2 selectively in immune cells, the company's lead candidate SR-878 simultaneously blocks multiple established pro-inflammatory pathways — TNF-alpha, IL-6R, and EGFR/HB-EGF signaling — while preserving protective TACE functions in epithelial tissues, a profile designed to address the 30-40% of autoimmune patients who do not adequately respond to existing biologics. SciRhom is developing SR-878 and the broader Anti-iRhom2 Antibody Platform for rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological indications, with first-in-human dosing initiated in October 2024 in Austria and a Phase 1 readout expected in H2 2025.
The company is pre-revenue and monetizes via eventual commercialization of approved antibody products through traditional pharmaceutical channels; currently it funds operations almost entirely through venture capital, having raised approximately EUR 79 million to date (EUR 16M seed plus an oversubscribed EUR 63M Series A in July 2024 co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners). SciRhom's go-to-market posture is enterprise-oriented, relying on academic medical centers for clinical development (e.g., Medical University of Vienna), WuXi Biologics for CMC and manufacturing, and a Clinical Advisory Board of leading rheumatologists for scientific and clinical guidance. Four granted patent families protect the iRhom2-targeting technology, and the management team combines Max Planck/U3 Pharma/Daiichi Sankyo antibody development pedigree with senior commercial and clinical leadership from Boehringer Ingelheim.
Customer relationships are forward-looking: there are no commercial customers today, and end-users are patients with autoimmune diseases (segmented primarily as autoimmune disease patients and secondarily as dermatological disease patients) who will access the therapy only after regulatory approval and commercialization. The target end-markets are large, fragmented therapeutic categories in which SciRhom will compete against established biologics (anti-TNF, anti-IL-6R) on the basis of multi-pathway inhibition and a differentiated safety profile.
SciRhom firmographics
Firmographics- Name
- SciRhom
- Legal name
- SciRhom GmbH
- Website
- https://scirhom.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SciRhom GmbH is a clinical-stage German biotech developing first-in-class anti-iRhom2 monoclonal antibody therapies for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
- Ownership category
- akta.pro rank
SciRhom industry classification
Industry- Product category
- Biopharmaceutical Antibody Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industry
- Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)
Keywords
Where SciRhom is headquartered
LocationHeadquarters
- HQ city
- Martinsried
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
SciRhom business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Pre-revenue company developing antibody therapies for autoimmune diseases. Revenue will be generated through commercialization of approved therapeutic products, initially targeting rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
SciRhom product offering
Product offeringCore offering
SciRhom is a clinical-stage biotech developing first-in-class humanized monoclonal antibodies that target iRhom2 (RHBDF2), a key regulator of the TACE/ADAM17 protease. Its lead candidate SR-878 simultaneously blocks multiple pro-inflammatory pathways (TNF-alpha, IL-6R, EGFR) while preserving protective TACE functions, and is being advanced through Phase 1 clinical trials for rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. The company also maintains a broader Anti-iRhom2 Antibody Platform protected by four patent families as the foundation for follow-on programs.
Product overview
SciRhom is a biopharmaceutical company developing first-in-class iRhom2-targeting antibody therapies for autoimmune diseases. The company's core product is SR-878, a monoclonal antibody currently in Phase 1 clinical development, supported by the Anti-iRhom2 Antibody Platform which underlies the therapeutic approach. The platform enables targeting of iRhom2/TACE pathway to simultaneously block TNF-alpha, IL-6R, and EGFR signaling while preserving protective functions. Development pipeline includes rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- SR-878 A first-in-class humanized monoclonal antibody targeting iRhom2 (inactive Rhomboid 2/RHBDF2), designed to simultaneously block multiple pro-inflammatory signaling pathways including TNF-alpha, IL-6R, and EGFR while preserving protective functions of TACE/ADAM17. Currently in Phase 1 clinical development for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
- Anti-iRhom2 Antibody Platform Proprietary platform technology for developing first-in-class therapeutic antibodies targeting iRhom2, a critical regulator of TACE/ADAM17. The platform enables simultaneous blockade of multiple pro-inflammatory pathways with an expected favorable safety profile compared to direct TACE inhibitors. Four patent families protect the technology and provide exclusivity against follow-on drugs.
Quantifiable outcome
- Addresses the 30-40% of autoimmune patients who do not respond to existing biologics
- +2 more outcomes
Companies that use SciRhom
Customer profileSegments2 records
Ideal customer profiles1 record
SciRhom technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SciRhom partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Prof. Carl Blobel / Hospital for Special SurgerycoreCo-founder of SciRhom. Prof. Blobel made seminal contributions to understanding how iRhom2 controls TACE/ADAM17 activity. His research at Hospital for Special Surgery in New York City formed the scientific foundation for SciRhom's anti-iRhom2 antibodies.
- WuXi BiologicscoreTop-tier biopharmaceutical manufacturer engaged for CMC development and manufacturing of SR-878 clinical candidate. Established robust biopharmaceutical manufacturing process producing high yields with excellent antibody properties.
- Medical University of ViennacoreClinical trial partnership for first-in-human study of SR-878. The Department of Clinical Pharmacology at Medical University of Vienna is conducting the Phase 1 clinical trial.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
SciRhom competitors and assessment
Company assessmentBroad incumbents
- UCB: Specialty immunology company marketing Cimzia (certolizumab, anti-TNF) and Rinvoq (JAK inhibitor) in RA, IBD, and other autoimmune indications. Competes in the same autoimmune disease space SciRhom is targeting.
- AbbVie: Global biopharmaceutical company with Humira (adalimumab) and Skyrizi/Rinvoq in autoimmune diseases, the dominant TNF-alpha inhibitor franchise that SciRhom's anti-iRhom2 antibodies aim to outperform in RA/IBD patients with inadequate response.
- Johnson & Johnson (Janssen): Markets Stelara, Tremfya, and Remicade in autoimmune diseases including RA, IBD, and lupus. A leading incumbent whose IL-12/23 and IL-23 inhibitors compete directly for the autoimmune patient population SciRhom targets.
- Roche / Genentech: Markets Actemra (tocilizumab, anti-IL-6R) in RA and other autoimmune indications. Directly comparable because SciRhom's anti-iRhom2 antibodies block IL-6R signaling (among other pathways) as part of a multi-pathway mechanism.
- Amgen: Markets Enbrel (etanercept, TNF inhibitor) and Otezla (PDE4 inhibitor) in RA, psoriasis, and IBD. Competes in the autoimmune space SciRhom addresses and has deep rheumatology commercial capabilities.
- Sanofi: Markets Dupixent (dupilumab, anti-IL-4R) in multiple autoimmune and inflammatory indications including atopic dermatitis and IBD. A relevant incumbent competing for the autoimmune patient segments SciRhom ultimately aims to serve.
- Eli Lilly: Markets Olumiant (baricitinib, JAK inhibitor) and Taltz (ixekizumab, anti-IL-17) in RA and other autoimmune indications. Active acquirer of autoimmune biotechs (e.g., Dice Therapeutics) and a potential strategic partner or competitor for SciRhom.
- Bristol Myers Squibb: Markets Zeposia (S1P modulator) and Sotyktu (TYK2 inhibitor) in autoimmune diseases including IBD and psoriasis. A relevant incumbent in the autoimmune space and a frequent partner/acquirer of clinical-stage biotechs.
Emerging players
- argenx: Clinical-stage immunology biotech with lead FcRn antagonist Vyvgart (efgartigimod) approved in autoimmune indications, advancing a pipeline of antibody therapeutics for autoimmune disease — comparable to SciRhom as a focused autoimmune antibody developer.
- AnaptysBio: Clinical-stage antibody therapeutics company developing immunology-focused programs (rosnilimab, ANB033) for autoimmune and inflammatory diseases, with a similar biotech-stage profile and antibody-platform approach to SciRhom.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
SciRhom social profiles
Digital presenceSciRhom financial estimates
Financial estimateRevenue estimate
Valuation estimate
SciRhom leadership team
Management profileNumber of profiles
Profiles4 records
SciRhom funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SciRhom M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SciRhom
What does SciRhom do?
SciRhom is a clinical-stage biotech developing first-in-class humanized monoclonal antibodies that target iRhom2 (RHBDF2), a key regulator of the TACE/ADAM17 protease. Its lead candidate SR-878 simultaneously blocks multiple pro-inflammatory pathways (TNF-alpha, IL-6R, EGFR) while preserving protective TACE functions, and is being advanced through Phase 1 clinical trials for rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. The company also maintains a broader Anti-iRhom2 Antibody Platform protected by four patent families as the foundation for follow-on programs.
Is SciRhom a public or private company?
SciRhom is a private company. It is classified as venture growth investor backed and is currently operating.
When was SciRhom founded?
SciRhom was founded in 2016. It employs 11 to 50 people.
Where is SciRhom based?
SciRhom is headquartered in Martinsried, Germany, in the Europe region.
How does SciRhom make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are SciRhom's main competitors?
Broad incumbents on record are UCB, AbbVie, Johnson & Johnson (Janssen), Roche / Genentech, Amgen, Sanofi, Eli Lilly and Bristol Myers Squibb. Emerging players are argenx and AnaptysBio.
Does SciRhom have an API?
No public API is recorded for SciRhom.
What industry is SciRhom in?
SciRhom's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.